Pulse Biosciences (PLSE)
NASDAQ:PLSE
Want to see PLSE full AI Analyst Report?
PLSE Stock Chart & Stats
$23.40
-$0.27(-1.46%)
At close: 4:00 PM EST
$23.40
-$0.27(-1.46%)
Day’s Range― - ―
52-Week Range$12.56 - $26.30
Previous CloseN/A
Volume31.18K
Average Volume (3M)189.63K
Market Cap
$1.37B
Enterprise Value$1.21B
Total Cash (Recent Filing)$80.73M
Total Debt (Recent Filing)$7.53M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Aug 17, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding68,225,070
10 Day Avg. Volume222,519
30 Day Avg. Volume189,626
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)11.47
Price to Sales (P/S)2643.82
P/FCF Ratio-17.00
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue3.46K
Enterprise Value/Gross Profit-1.69K
Enterprise Value/Ebitda-16.60
Forecast
1Y Price Target
$30.00Price Target Upside28.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.18
Revenue Forecast (FY)$3.50M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyRobust, reproducible clinical results materially de‑risk regulatory and reimbursement pathways and support faster physician adoption. Durable efficacy and short procedure times strengthen the technology’s clinical value proposition and long‑term commercial potential in AF ablation.
Intellectual PropertyA large, growing patent estate creates structural barriers to entry for competitors, supports licensing or partnership leverage, and protects differentiated nsPFA know‑how. This IP depth strengthens long‑term market defensibility for device and consumable revenue streams.
Recurring Consumables ModelA capital‑plus‑consumables business model offers a path to recurring, higher‑margin revenues as installed base grows. Durable procedure volume drives disposables demand, improving unit economics over time and enabling aftermarket, service, and consumable revenue scalability.
Bears Say
Minimal Revenue BaseVery limited current revenue and negligible gross margin indicate the business has not yet achieved commercial scale. Without material top‑line growth, the company cannot cover fixed R&D and G&A, making long‑term self‑funding and margin sustainability uncertain.
Accelerating Cash BurnConsistent, large operating outflows and declining cash reserves create runway pressure during multi‑quarter pivotal trials and commercialization build‑out. The need for external capital raises dilution risk and could slow execution if financing is delayed or terms are unfavorable.
Regulatory/Reimbursement DependencyCommercial scale depends on successful IDE/pivotal outcomes, CE/FDA clearances and reimbursement traction. These multi‑quarter, interdependent milestones extend time to meaningful revenue, increase execution risk, and elevate reliance on partnerships or external financing for commercialization.
Pulse Biosciences News
PLSE FAQ
What was Pulse Biosciences’s price range in the past 12 months?
Pulse Biosciences lowest stock price was $12.56 and its highest was $26.30 in the past 12 months.
What is Pulse Biosciences’s market cap?
Pulse Biosciences’s market cap is $1.37B.
When is Pulse Biosciences’s upcoming earnings report date?
Pulse Biosciences’s upcoming earnings report date is Aug 17, 2026 which is in 103 days.
How were Pulse Biosciences’s earnings last quarter?
Pulse Biosciences released its earnings results on May 04, 2026. The company reported -$0.238 earnings per share for the quarter, beating the consensus estimate of -$0.27 by $0.032.
Is Pulse Biosciences overvalued?
According to Wall Street analysts Pulse Biosciences’s price is currently Undervalued.
Does Pulse Biosciences pay dividends?
Pulse Biosciences does not currently pay dividends.
What is Pulse Biosciences’s EPS estimate?
Pulse Biosciences’s EPS estimate is -0.28.
How many shares outstanding does Pulse Biosciences have?
Pulse Biosciences has 68,225,070 shares outstanding.
What happened to Pulse Biosciences’s price movement after its last earnings report?
Pulse Biosciences reported an EPS of -$0.238 in its last earnings report, beating expectations of -$0.27. Following the earnings report the stock price went down -3.841%.
Which hedge fund is a major shareholder of Pulse Biosciences?
Currently, no hedge funds are holding shares in PLSE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulse Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.00 (28.21% Upside)
$30.00 (28.21% Upside)
Blogger Sentiment
Bullish
PLSE Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 11.6K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.46%
12-Months-Change
Fundamentals
Return on Equity
-73.46%
Trailing 12-Months
Asset Growth
-28.30%
Trailing 12-Months
Company Description
Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
PLSE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed strong clinical and technology progress—IDE approvals, compelling early efficacy data with high 12‑month success rates, rapid procedure times, and substantial IP expansion—which materially de-risks key scientific and regulatory milestones. However, the financial picture remains early-stage: product revenue is still nominal, gross margin was effectively negligible in the quarter, operating losses persist, cash reserves declined substantially year-over-year, and broader commercialization hinges on additional regulatory clearances and reimbursement processes that may take multiple quarters. Overall, the narrative balances important clinical/strategic momentum against clear near-term financial and commercialization constraints.View all PLSE earnings summariesPLSE Stock 12 Month Forecast
Average Price Target
$30.00
▲(28.21% Upside)
Technical Analysis
Ownership Overview
73.08% Insiders
2.27% Mutual Funds
0.43% Other Institutional Investors
21.48% Public Companies and
Individual Investors